Norges Bank’s Seres Therapeutics MCRB Stock Holding History

Norges Bank’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,516	Closed	-$743K	–	2172
2020 Q4	$743K	Buy	+1,516	New	+$888K	﹤0.01%	2054
2015 Q3	–	Sell	-1,000	Closed	-$830K	–	2310
2015 Q2	$830K	Buy	+1,000	New	+$873K	﹤0.01%	2145

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank's MCRB Position: Q1 2021 in Review

Norges Bank sold out of Seres Therapeutics (MCRB) in Q1 2021, closing a stake of 1,516 shares — an estimated $743K sold.

Norges Bank first reported a position in MCRB in Q2 2015 and held it in 2 quarters. The position peaked at $830K in Q2 2015. 152 funds tracked by Wall St. Rank hold MCRB as of Q1 2021.

Norges Bank reported no remaining Seres Therapeutics position as of Q1 2021 after selling out during the quarter.
Norges Bank sold 1,516 Seres Therapeutics shares in Q1 2021, an estimated $743K.
Norges Bank first reported a position in Seres Therapeutics in Q2 2015 and held it in 2 quarters.
Norges Bank's Seres Therapeutics position peaked at $830K in Q2 2015.
152 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2021.

Based on Norges Bank's 13F filing for Q1 2021, filed 7 May 2021.